Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1600 1611 1613 1632 1635 1636 1638 1642 1796 4100
This examiner grants 58% of resolved cases
Catherine Anne Konopka is an examiner in Art Unit 1600 of Tech Center 4100. She has 203 resolved cases and an allowance rate of 58.1%. This rate shows that a majority of the applications she examines result in an allowance. The 58.1% allowance rate is a figure for understanding the probability of success with this examiner.
The interview lift is 65.0%, which is higher than the 58.1% allowance rate. This suggests that interviews are a successful tactic for resolving issues and securing a grant. The median days to allowance is 1393, which is a period for applicants to consider. By analyzing the 203 resolved cases and the 65.0% interview lift, practitioners can see that direct engagement is a strategy for navigating the 1393-day median timeline to allowance in Art Unit 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18267144 | METHOD FOR PROGRAMMABLE CONTROL OF RNA TRANSCRIPT LEVELS WITH AUTOREGULATED CRISPR-CAS13D | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18045873 | AAV VARIANTS WITH HOST ANTIBODY ESCAPE CAPABILITIES AND ALTERED TISSUE TARGETING PROPERTIES | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18553357 | Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18213505 | MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17921027 | IMPROVED CAS 12A/NLS MEDIATED THERAPEUTIC GENE EDITING PLATFORMS | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18752501 | MULTI-VECTOR RECOMBINASE MEDIATED CASSETTE EXCHANGE | Non-Final OA | Genentech, Inc. |
| 18712524 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Non-Final OA | Ohio State Innovation Foundation |
| 18571967 | COMPOSITIONS AND METHODS FOR IMPROVED PROTEIN TRANSLATION FROM RECOMBINANT CIRCULAR RNAS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18303527 | PROGRAMMABLE GENE EDITING USING GUIDE RNA PAIR | Non-Final OA | Massachusetts Institute of Technology |
| 18048238 | DISCOVERY AND ENGINEERING OF INTEGRASES FOR HIGH-EFFICIENCY GENE INTEGRATION | Non-Final OA | Massachusetts Institute of Technology |
| 18535658 | SYNTHETIC IMMUNOMODULATION WITH A CRISPR SUPER-REPRESSOR IN VIVO | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18246408 | CORONAVIRUS REPLICONS FOR ANTIVIRAL SCREENING AND TESTING | Non-Final OA | MERCK SHARP & DOHME LLC |
| 17596186 | SYSTEM AND METHOD FOR COMBATING MYCOBACTERIUM TUBERCULOSIS INFECTIONS | Final Rejection | Tata Consultancy Services Limited |
| 18798198 | Treatment Of Hyperglycemia With Solute Carrier Family 39 Member 5 (SLC39A5) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18385174 | CD70-TARGETED MICELLES ENHANCE HIF2a siRNA DELIVERY AND INHIBIT ONCOGENIC FUNCTIONS IN PATIENT-DERIVED CLEAR CELL RENAL CARCINOMA CELLS | Non-Final OA | University of Southern California |
| 18014692 | USE OF SATIVENE, AND RECOMBINANT BIOCONTROL FUNGUS AND MUSCARDINE CADAVER AND USE THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18257504 | CHEMICALLY MODIFIED CRISPR-CAS13 GUIDE RNAS | Final Rejection | New York University |
| 17756078 | LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF T CELLS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18265226 | COMPOSITIONS TARGETING WDR37 AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18506637 | COMPOSITIONS AND METHODS OF USE FOR MUTATED HOTAIR IN THE TREATMENT OF CANCERS | Non-Final OA | The Regents of the University of Colorado, a body corporate |
| 16174759 | MANUFACTURING METHOD OF NANODISC COMPRISING AN OLFACTORY RECEPTOR PROTEIN AND NANODISC COMPRISING AN OLFACTORY RECEPTOR PROTEIN MANUFACTURED BY THE SAME | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18659831 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF HBV | Non-Final OA | Hoffmann-La Roche Inc. |
| 18711241 | NOCICEPTOR-SPECIFIC GENE REGULATORY ELEMENTS FOR THE TREATMENT OF PAIN | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18412351 | COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIER | Non-Final OA | FRED HUTCHINSON CANCER CENTER |
| 18547102 | FOLLICULIN iRNA COMPOSITIONS AND METHODS THEREOF | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 18555012 | RNA INHIBITOR FOR INHIBITING HEPATITIS B VIRUS GENE EXPRESSION AND APPLICATION THEREOF | Non-Final OA | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. |
| 17985974 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1 (TMC1) | Final Rejection | Korro Bio, Inc. |
| 18251183 | COMPOSITIONS COMPRISING AN RNA GUIDE TARGETING BCL11A AND USES THEREOF | Final Rejection | Arbor Biotechnologies, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy